Compositions and Methods for Treating Metabolic Disorders
AssigneeElcelyx Therapeutics, Inc.
InventorsAlain D. BARON, Mark S. FINEMAN, Nigel R. A. BEELEY
Life of this patent
Estimating the term…
Abstract
Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.
Claims25
A method of improving the gastrointestinal tolerability of and/or reducing gastrointestinal complications resulting from biguanide administration, comprising administering a therapeutically effective amount of a biguanide compound in a delayed-release formulation to a patient in need thereof.
A method of treating metabolic disorders in a patient in need thereof, comprising administering a therapeutically effective amount of a biguanide compound to said patient in a delayed-release formulation, wherein said patient has a contraindication for the biguanide compound.
The method according to any one of the preceding claims, wherein the patient in need thereof has hyperglycemia.
A method of treating a renally impaired subject having diabetes, comprising administering a therapeutically effective amount of a biguanide compound to said subject in a delayed-release formulation.
A method of treating a diabetic subject having congestive heart failure, a hypoxic state and/or advanced liver disease, comprising administering a therapeutically effective amount of a biguanide compound to said subject in a delayed-release formulation.
A method of reducing the onset of diabetes in a subject with pre-diabetes, comprising administering a therapeutically effective amount of a biguanide compound to said subject in a delayed-release formulation.
A method of inducing weight loss in a subject, comprising administering a therapeutically effective amount of a biguanide compound to said subject in a delayed release formulation.
The method according to any one of the preceding claims, wherein the biguanide compound is targeted for delivery to the small intestine, and the formulation comprises an oral dosage form enterically coated at a pH at or above 5.0 or 5.5.
The method according to any one of the preceding claims, wherein said biguanide compound is selected from the group consisting of metformin, phenformin, buformin and imeglimin.
A method according to any one of the previous claims, further comprising administration of a DPP-IV inhibitor.
A method according to any one of the previous claims, further comprising administration of an anti-obesity or anti-diabetes agent.
Dependencies are inferred from the claim text.